Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We investigated the relationship between smoking status and depression symptom score in a large prospective cohort of women (n = 7,089) followed at regular intervals during and immediately following pregnancy. We wished to determine whether depression symptom score predicts subsequent likelihood of failed or successful smoking cessation attempts, and whether smoking cessation during and immediately following pregnancy is associated with change in depression symptom score. Longitudinal latent class analysis was used to empirically derive smoking trajectories. These latent smoking classes were characterized using adversity measures collected at baseline. Depression symptom score at baseline was used to attempt to predict class membership. The mean depression symptom score and change in depression symptom score was calculated within each smoking trajectory for each time point. We identified seven distinct smoking trajectories, with five reflecting a transition from smoking to nonsmoking, and in four of these a relapse back to smoking. Depression symptom score at baseline did not strongly differentiate between smoking trajectories. Those that resulted in abstinence demonstrated the lowest depression symptom scores at that time point. The analysis of change in depression symptom score suggested different relationships between depression symptom score, smoking cessation, and relapse among the various trajectories. Our data suggest the relationship between depression symptom score and smoking status may differ across the trajectories we identified. In general, smoking cessation appears to be associated with a reduction in depression symptom score. Future studies should explore this possibility in more detail, including whether these relationships differ in clinical and nonclinical samples.
Nicotine Tob Res 2008 Nov
PMID:Smoking patterns during pregnancy and postnatal period and depressive symptoms. 1898 73

The National Institute of Mental Health (NIMH) convened a meeting in September 2005 to review tobacco use and dependence and smoking cessation among those with mental disorders, especially individuals with anxiety disorders, depression, or schizophrenia. Smoking rates are exceptionally high among these individuals and contribute to the high rates of medical morbidity and mortality in these individuals. Numerous biological, psychological, and social factors may explain these high smoking rates, including the lack of smoking cessation treatment in mental health settings. Historically, "self-medication" and "individual rights" have been concerns used to rationalize allowing ongoing tobacco use and limited smoking cessation efforts in many mental health treatment settings. Although research has shown that tobacco use can reduce or ameliorate certain psychiatric symptoms, overreliance on the self-medication hypothesis to explain the high rates of tobacco use in psychiatric populations may result in inadequate attention to other potential explanations for this addictive behavior among those with mental disorders. A more complete understanding of nicotine and tobacco use in psychiatric patients also can lead to new psychiatric treatments and a better understanding of mental illness. Greater collaboration between mental health researchers and nicotine and tobacco researchers is needed to better understand and develop new treatments for cooccurring nicotine dependence and mental illness. Despite an accumulating literature for some specific psychiatric disorders and tobacco use and cessation, many unstudied research questions remain and are a focus and an emphasis of this review.
Nicotine Tob Res 2008 Dec
PMID:Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. 1902 23

We evaluated the effects of Nicotine Replacement Therapy (NRT) on the Profile of Mood States (POMS), testing whether pre-cessation depressive symptoms modify NRT's effects on POMS. Out of 608 smokers attempting to quit with NRT, this secondary analysis included 242 participants abstinent for at least two weeks. We measured pre-cessation depressive symptoms with the Center for Epidemiological Studies Depression Scale. At 1, 7, and 14 post-cessation days we examined 6 self-reported POMS, i.e. feeling 'anxious', 'sad', 'confused', 'angry', 'energetic' and 'fatigue'. The results of the ANCOVA models suggested no NRT effects on feeling anxious, energetic or fatigue. We found that pre-cessation depression modified NRT effects in some specific mood states, such as depression by NRT- interaction effects on feeling confused and feeling angry. On average, the depressed participants in the placebo groups had the highest symptom scores. However, those depressed in NRT conditions did not have significantly higher symptom scores compared to the non-depressed groups. In treating those negative moods NRT may be particularly important for persons with depressive symptoms before cessation.
Tob Induc Dis 2006 Aug 15
PMID:Impact of Nicotine Replacement Therapy on post-cessation mood profile by pre-cessation depressive symptoms. 1957 Feb 94

Objective: We estimated whether recent cannabis use moderates response to cigarettes varying in nicotine content (0.4, 2.4, 5.2, 15.8 mg/g) among smokers with concurrent affective disorders, opioid dependence, or socioeconomic disadvantage. Methods: We conducted a secondary analysis of a multi-site, double-blind, laboratory study examining acute response to reduced nicotine content cigarettes (RNCC) in 169 adult smokers with co-morbid conditions. Participants positive for recent cannabis use or self-reported past 30-day cannabis use at baseline were categorized as current cannabis users (N = 63). Repeated measures analysis of variance tests assessed whether baseline cannabis use moderated cigarette reinforcement, tobacco withdrawal, craving, smoking topography, or carbon monoxide boost. Results: Cannabis users were younger, less educated, and had more depression and anxiety than non-users (p < .05). Cannabis use status did not moderate the effects of nicotine dose on concurrent choice testing, subjective effects of RNCCs, or smoking topography. After adjusting for sociodemographic characteristics, cannabis users had higher ratings on Smoking Satisfaction, Enjoyment of Respiratory Tract Sensations, and Craving Reduction across all nicotine doses. Cannabis users reported longer withdrawal symptom duration and more rapid decline of carbon monoxide boost than non-users. Conclusions: Findings suggest RNCCs decrease the addiction potential of cigarettes in vulnerable populations independent of cannabis use status.
Tob Regul Sci 2018 Sep
PMID:Reduced Nicotine Content Cigarettes and Cannabis Use in Vulnerable Populations. 3041 34


<< Previous 1 2 3 4 5 6